Indirubin Derivative E804A cell-permeable inhibitor of Src-Stat3 signaling pathway

Indirubin Derivative E804 (CAS 854171-35-0)

Indirubin Derivative E804 | CAS 854171-35-0 is rated 5.0 out of 5 by 1.
  • y_2019, m_9, d_19, h_8
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_221751, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 71ms
  • REVIEWS, PRODUCT
Synonym: IDR E804
Application: A cell-permeable inhibitor of Src-Stat3 signaling pathway
CAS Number: 854171-35-0
Purity: ≥95%
Molecular Weight: 365.39
Molecular Formula: C20H19N3O4
* Refer to Certificate of Analysis for lot specific data (including water content).

Indirubin Derivative E804 is a cell-permeable indirubin derivative (IDR) that inhibits the Src-Stat3 signaling pathway and displays anti-tumor properties. A potent, ATP-competitive inhibitor of the kinase activities of Src. Indirubin Derivative E804 decreases tyrosine phosphorylation levels of Src, JAK1, and Stat3 in MDA-MB-468 cells in a time- and dose-dependent manner. Selectively induces apoptosis in cells expressing high levels of active Stat3. Indirubin Derivative E804 is an inhibitor of Cdc2, Cdk2 and SRC.


References

1. Nam, S. et al. 2005. Proc. Natl. Acad. Sci. U.S.A. 102(17): 5998-6003. PMID: 15837920

Physical State :
Solid
Solubility :
Soluble in DMSO (200 mg/ml).
Storage :
Store at -20° C
Melting Point :
262.70° C (Predicted)
Boiling Point :
719.8° C at 760 mmHg (Predicted)
Density :
1.4 g/cm3 (Predicted)
Refractive Index :
n20D 1.70 (Predicted)
IC50 :
Kinase activities of Src: IC50 = 430 nM; Cdk1/cyclin E : IC50 = 210 nM; Cdk2/cyclin A: IC50 = 540 nM; Cdk1/cyclin B : IC50 = 1.65 µM; Interferon-induced, double-stranded RNA-activated protein kinase: IC50 = <100 nM (human)
pK Values :
pKa: 10.55 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
6419764
SMILES :
C1=CC=C2C(=C1)C(=C(N2)C3=C4C=CC=CC4=NC3=O)NOCCC(CO)O

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 72ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from A decrease in Mcl A decrease in Mcl-1 expression was observed in MDA-MB-468 cells by WB when comparing untreated cells with those that have been treated with Indirubin Derivative E804, a cell permeable inhibitor of Src-Stat3. -SCBT QC
Date published: 2015-05-18
  • y_2019, m_9, d_19, h_8
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_221751, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 39ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.